ATP-sensitive K+ (KATP) channel blockers are prescribed to individuals who are in the diabetes-aged population and who display impaired glucose-induced insulin release (Gribble and Reimann 2003; Arnoux et al. 2010; Ashcroft 2010). Here, INS is linked to diabetes mellitus.